Zelasudil, an experimental treatment for idiopathic pulmonary fibrosis (IPF) that’s now being tested in clinical trials, has been granted orphan drug status by the U.S. Food and Drug Administration (FDA). The FDA awards this designation to therapies with the potential to substantially improve care for people with rare diseases,…
The end of life is a period fraught with emotion. Losing someone who touched our lives creates a sudden void. I’ve witnessed alliances form following the passing of a family member, usually because there are opposing views of what the recently deceased would want. These rifts don’t always heal. But…
Many people with idiopathic pulmonary fibrosis (IPF) in the U.S. are not diagnosed early enough or given treatments helping to low its progression in a timely fashion, a large data study found. Although more is known about risk factors for IPF, delays are evident in diagnosis and the…
GB0139, an investigational inhaled treatment for idiopathic pulmonary fibrosis (IPF), failed to slow lung decline in IPF patients compared with a placebo, according to top-line data from the Phase 2b GALACTIC-1 trial. GB0139’s developer Galecto will discontinue the treatment. “We are very disappointed that the GALACTIC-1 results…
Idiopathic pulmonary fibrosis (IPF) is a complex disease that leads me and other patients on a complicated trajectory. Not only do I deal with its physical difficulties, such as acute exacerbations and oxygen dependency, but I also wrestle with its emotional and social complexities. Since being diagnosed…
Writing “Make Every Breath Count” for you each week is an opportunity for me to share my journey, which is a form of therapy for me. It’s an outlet to process my experiences with idiopathic pulmonary fibrosis (IPF) and receiving a bilateral lung transplant. Recently, my column…
Trevi Therapeutics is planning to launch two new clinical trials this fall to test Haduvio (nalbuphine extended-release tablets) for chronic cough in people with idiopathic pulmonary fibrosis (IPF). One of the trials will be a Phase 2b study to identify the best dose of the medication for…
Bexotegrast, an oral anti-fibrotic treatment candidate from Pliant Therapeutics, is being assessed in a Phase 2b clinical trial in people with idiopathic pulmonary fibrosis (IPF). Called BEACON-IPF, it intends to recruit about 270 patients at clinical sites around the globe. Details on site locations and when recruitment will start…
Some of the most important interactions in our professional lives do not occur at work, at the boardroom table, or even in an office. Often, they occur during brief introductions or chance meetings. The challenge for business leaders regardless of industry is how to briefly explain to someone what they…
Suppressing the production of a protein called NPAS2Â eased signs of lung scarring (fibrosis) in a mouse model of idiopathic pulmonary fibrosis (IPF), a new study showed. The NPAS2 gene, which codes for NPAS2, also was found to be more active in the lungs of IPF patients than in those…
Get regular updates to your inbox.
